Table 4.
Impact of EGFR polymorphisms on histopathological features and prognostic estimates of breast cancer
| |
R497K
variant genotypes |
(CA)n
variant genotypes |
EGFR
combined variant genotypes |
|||||
|---|---|---|---|---|---|---|---|---|
|
Lymph node status |
TNM status |
ERR |
PR status |
TNM status |
ERR |
TNM status |
ERR |
|
|
Tumor stratification |
N2/N3 |
≥ IIIA |
High |
negative |
≥ IIIA |
High |
≥ IIIA |
High |
|
OR adjusted |
OR adjusted |
OR |
OR adjusted |
OR adjusted |
OR |
OR adjusted |
OR |
|
|
(IC95%) |
(IC95%) |
(IC95%) |
(IC95%) |
(IC95%) |
(IC95%) |
(IC95%) |
(IC95%) |
|
| P | P | P | P | P | P | P | P | |
| Complete cohort |
0.32 |
0.34 |
0.50 |
0.42 |
0.74 |
0.74 |
0.22 |
0.25 |
| |
(0.17-0.59) |
(0.19-0.63) |
(0.30-0.81) |
(0.19-0.91) |
(0.40-1.32) |
(0.43-1.25) |
(0.07-0.75) |
(0.09-0.71) |
|
< 0.001 |
0.001 |
0.005 |
0.030 |
0.53 |
0.26 |
0.018 |
0.005 |
|
| Luminal A |
0.34 |
0.38 |
0.35 |
NA |
0.62 |
0.60 |
0.32 |
0.24 |
| |
(0.15-0.75) |
(0.18-0.80) |
(0.17-0.75) |
|
(0.29-1.36) |
(0.27-1.32) |
(0.092-1.12) |
(0.06-1.03) |
|
0.007 |
0.011 |
0.005 |
|
0.22 |
0.20 |
0.075 |
0.038 |
|
| Luminal B |
0.057 |
0.060 |
0.58 |
0.080 |
1.29 |
1.29 |
NC |
0.61 |
| |
(0.006-0.53) |
(0.007-0.53) |
(0.21-1.60) |
(0.012-0.54) |
(0.35-4.72) |
(0.48-3.48) |
|
(0.12-3.10) |
|
0.012 |
0.012 |
0.29 |
< 0.001 |
0.26 |
0.62 |
|
0.54 |
|
| HER2-like |
0.18 |
0.22 |
0.27 |
NA |
1.14 |
2.91 |
NC |
NC |
| |
(0.02-2.02) |
(0.02-2.28) |
(0.05-1.64) |
|
(0.15-8.59) |
(0.27-31.21) |
|
|
| 0.18 |
0.22 |
0.14 |
|
0.90 |
0.36 |
|
|
|
| Triple negative |
5.2 |
5.1 |
2.0 |
NA |
NC |
NC |
NC |
NC |
| |
(0.48-55.27) |
(0.48-54.03) |
(0.48-8.40) |
|
|
|
|
|
| 0.17 | 0.18 | 0.349 | ||||||
R497K variant genotypes include Arg/Lys and Lys/Lys. The genotype Arg/Arg was taken as reference for OR calculation; (CA)n variant genotypes include two Long alleles in combination (Long/Long), where the Long allele corresponds to (CA)n lengths with more than 16 repeats. The genotypes Short/Short and Short/Long were considered together as reference for OR calculation. EGFR combined variants include patients with genotypes Arg/Lys or Lys/Lys for R497K and Long/Long for (CA)n. The reference genotypes were R497K Arg/Arg and (CA)n Short/Short or Short/Long. The OR calculation for lymph node status was adjusted for age, hystological type, tumor grade, tumor size, and for ER, PR and HER2 status. The OR calculation for PR status was adjusted for age, hystological type, tumor grade, tumor size, lymph node status and for ER and HER2 status. The OR calculation for TNM status was adjusted for age, hystological type, tumor grade and for ER, PR and HER2 status. Statistically significant differences are presented in bold characters. Abbreviations: TNM Tumor staging according to tumor size, lymph node status and distant metastases, ERR Estimated Recurrence Risk, PR Progesterone Receptor, HER2 Human Epidermal growth factor Recetor 2, NA not applicable, NC not calculated (the number of samples was not sufficient for OR calculation).